|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 重组脊髓灰质炎病毒用于治疗复发胶质母细胞瘤(英文)显示文摘Background The prognosis of patients with recurrent World Health Organization(WHO)grade IV malignant glioma is dismal,and there is currently no effective therapy.We conducted a dose-finding and toxicity study in this population of patients,evaluating convection-enhanced,intratumoral delivery of the recombinant nonpathogenic polio-rhinovirus chimera(PVSRIPO).PVSRIPO recognizes the poliovirus receptor CD155,which is widely expressed in neoplastic cells of solid tumors and in major components of the tumor microenvironment.Methods We enrolled consecutive adult patients who had recurrent supratentorial WHO grade IV malignant glioma,confirmed on histopathological testing,with measurable disease(contrast-enhancing tumor of≥1 cm and≤5.5 cm in the greatest dimension).The study evaluated seven doses,ranging between 107 and 1010 50%tissue-culture infectious doses(TCID50),first in a dose-escalation phase and then in a dose-expansion phase.Results From May 2012 through May 2017,a total of 61 patients were enrolled and received a dose of PVSRIPO.Dose level-1(5.0×107TCID50)was identified as the phase 2 dose.One dose-limiting toxic effect was observed;a patient in whom dose level 5(1010TCID50)was administered had a grade 4 intracranial hemorrhage immediately after the catheter was removed.To mitigate locoregional inflammation of the infused tumor with prolonged glucocorticoid use,dose level 5 was deescalated to reach the phase 2 dose.In the dose-expansion phase,19%of the patients had a PVSRIPO-related adverse event of grade 3 or higher.Overall survival among the patients who received PVSRIPO reached a plateau of 21%(95%confidence interval,11 to 33)at 24 months that was sustained at 36 months.Conclusions Intratumoral infusion of PVSRIPO in patients with recurrent WHO grade IV malignant glioma confirmed the absence of neurovirulent potential.The survival rate among patients who receivedPVSRIPO immunotherapy was higher at 24 and 36 months than the rate among historical controls. | Desjardins A Gromeier M Herndon JE 2nd Beaubier N Bolognesi DP Friedman AH Friedman HS McSherry F Muscat AM Nair S Peters KB Randazzo D Sampson JH Vlahovic G Harrison WT McLendon RE Ashley D Bigner DD | 2018 | 中华神经外科疾病研究杂志2018，17，4： | 2 |
| 2 | Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins显示文摘 | Bolognesi A Tazzari P L Olivieri F | 1996 | Int J Cancer1996，68，3： | 1 |
| 3 | Ribosome-inactiva- ting proteins in edible plants and purification and character- ization of a new ribosome-inactivating protein from Cucurbita moscbata显示文摘 | Barbieri L Polito L Bolognesi A | 2006 | Biochim Biopbys Acta2006，1760，5： | 1 |
| 4 | In vitro and in vivoproperties of an anti-CD5-momordin immunotoxin on normal andneoplastic T lymphocytes显示文摘 | PORRO G BOLOGNESI A CARETTO P | 1993 | Cancer Immunol Immunother1993，36，5： | 1 |
| 5 | Inflammatory pseudotmnor of mediastinum treated with tomotherapy and monitored with FDG-PET/CT: case report and literature review 显示文摘 | Alongi F Bolognesi A Samanes Gajate AM | 2010 | Tumori2010，96，2： | 1 |
| 6 | Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins显示文摘 | Bolognesi A Tazzari PL Olivieri F | 1996 | Int J Cancer1996，68，3： | 1 |
| 7 | Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma显示文摘 | Giovanni Luca Ceresoli Laura Deborah Locati Andrés José Mar??a Ferreri Cesare Cozzarini Paolo Passoni Giulio Melloni Piero Zannini Angelo Bolognesi Eugenio Villa | 2001 | Lung Cancer2001，，2： | 1 |
| 8 | The allosteric regulation of pyruvate kinase显示文摘 | Mattevi A Bolognesi M Valentini G | 1996 | FEBS Lett1996，389，1： | 1 |
| 9 | Selenomethionine in- hibits IL-1β inducible nitric oxide synthase(iNOS) and cyclooxy- genase 2 (COX2) expression in primary human chondrocytes 显示文摘 | Cheng A W Stabler T V Bolognesi M | 2011 | Osteoarthritis Cartilage2011，19，1： | 1 |
| 10 | Toward a rational design of muhitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks显示文摘 | Bolognesi ML Cavalli A Bergamini C | 2009 | J Med Chem2009，52，23： | 1 |
| 11 | Docetaxel neuropa- thy: a distal axonopathy显示文摘 | Fazio R Quattrini A Bolognesi A | 1999 | Acta Neuropathol1999，98，6： | 1 |
| 12 | Purification and properties of new ribosome inactivating proteins with RNA N-glycosidase activity显示文摘 | Bolognesis A Barbieri L Abbondanza A | 1990 | Biochem Biophs Acta1990，1087，： | 1 |
| 13 | Targeting of type I ribosome-inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispicific antibodies显示文摘 | Sforzini S Bolognesi A Meazza R | 1995 | J Hematother1995，4，5： | 1 |
| 14 | Neuroglobin and cytoglobin, Fresh blood for the vertebrate globin family 显示文摘 | Pesce A Bolognesi M Bocedi A | 2002 | EMBO reports2002，3，12： | 1 |
| 15 | The HUMNxl scoring criteria for different cell types and nuclear anomalies in the buccal mi- cronucleus cytome assay - an update and expanded photogallery 显示文摘 | Bolognesi C Knasmueller S Nersesyan A | 2013 | Mutat Res2013，753，2： | 1 |
| 16 | The use of biomarkersin biomonitoring: A 2-tier approach assessing the level of pollu-tant-induced stress syndrome in sentinel organisms 显示文摘 | Viarengo A Lowe D Bolognesi C | 2007 | Compara-tive Biochemistry and Physiology C: Toxicology and Pharmacolo-gy2007，146，3： | 1 |
| 17 | Docetaxel neuropathy:a distal axonopathy显示文摘 | FAZIO R QUATTRINI A BOLOGNESI A | 1999 | Acta Neuropathol1999，98，6： | 1 |
| 18 | Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a tri- functional compound against Alzheimer's disease 显示文摘 | BOLOGNESI M L CAVALLI A VALGIMIGLI L | 2007 | J Med Chem2007，50，26： | 1 |
| 19 | High photoluminescence efficiency in substituted polythiophene aggregates显示文摘 | Bolognesi A Schieroni A G Botta C | 2003 | Synthetic Metals2003，139，2： | 1 |
| 20 | Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer, s disease 显示文摘 | Bolognesi NL Cavalli A Melchiorre C | 2009 | Neurotherapeu- tics2009，，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员